#	Pagina
attuale pagina	/open-h2020/projects/197244/index.html

Opendata, web and dolomites

IMMUTRAIN SIGNED

Training Network for the Immunotherapy of Cancer

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

IMMUTRAIN project word cloud

Explore the words cloud of the IMMUTRAIN project. It provides you a very rough idea of what is the project "IMMUTRAIN" about.

2013 therapies industrial expanding immune fifteen immutrain considerable union designed cancer trials rising efforts match bispecific antibody patient integral breakthrough death integrate nine placed highlighted accordingly therapy cells care coming occurring academic training immunotherapy leaders nucleic prestigious experimental combinatorial monoclonal total complementary individualized esr tumor synergies students sharpen outcome strategies create constantly skills dramatically industry immunotherapies reinforced young rationale heralding experts countries involvement sectors therapeutic antibodies innovative paradigm decade immunomodulatory medicine influence ph groups trained acute academia actively science network skilled seven journal dendritic acids incidence form clinical diversified stage forming

Project "IMMUTRAIN" data sheet

The following table provides information about the project.

Coordinator	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN Organization address address: GESCHWISTER SCHOLL PLATZ 1 city: MUENCHEN postcode: 80539 website: www.uni-muenchen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Germany [DE]
Project website	http://www.immutrain.eu
Total cost	3˙627˙525 €
EC max contribution	3˙627˙525 € (100%)
Programme	1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
Code Call	H2020-MSCA-ITN-2014
Funding Scheme	MSCA-ITN-ETN
Starting year	2015
Duration (year-month-day)	from 2015-12-01 to 2019-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN Organization address address: GESCHWISTER SCHOLL PLATZ 1 city: MUENCHEN postcode: 80539 website: www.uni-muenchen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENCHEN)	coordinator	996˙865.00
2	REGION HOVEDSTADEN REGION HOVEDSTADEN Organization address address: KONGENS VAENGE 2 city: HILLEROD postcode: 3400 website: www.regionh.dk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (HILLEROD)	participant	580˙163.00
3	FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III Organization address address: CALLE MELCHOR FERNANDEZ ALMAGRO 3 city: MADRID postcode: 28029 website: www.cnio.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (MADRID)	participant	495˙745.00
4	THE NOTTINGHAM TRENT UNIVERSITY THE NOTTINGHAM TRENT UNIVERSITY Organization address address: 50 SHAKESPEARE STREET city: NOTTINGHAM postcode: NG1 4FQ website: www.ntu.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (NOTTINGHAM)	participant	273˙287.00
5	INSTITUT GUSTAVE ROUSSY INSTITUT GUSTAVE ROUSSY Organization address address: Rue Camille Desmoulins 39 city: VILLEJUIF postcode: 94805 website: http://www.igr.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (VILLEJUIF)	participant	262˙875.00
6	MEDIZINISCHE UNIVERSITAT INNSBRUCK MEDIZINISCHE UNIVERSITAT INNSBRUCK Organization address address: CHRISTOPH PROBST PLATZ 1 city: INNSBRUCK postcode: 6020 website: www.i-med.ac.at contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AT (INNSBRUCK)	participant	255˙934.00
7	STICHTING KATHOLIEKE UNIVERSITEIT STICHTING KATHOLIEKE UNIVERSITEIT Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ website: www.radboudumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (NIJMEGEN)	participant	255˙374.00
8	ROCHE DIAGNOSTICS GMBH ROCHE DIAGNOSTICS GMBH Organization address address: Sandhofer Strasse 116 city: MANNHEIM postcode: 68305 website: www.roche-diagnostics.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MANNHEIM)	participant	249˙216.00
9	ISTITUTO EUROPEO DI ONCOLOGIA SRL ISTITUTO EUROPEO DI ONCOLOGIA SRL Organization address address: Via Filodrammatici 10 city: MILANO postcode: 20121 website: www.ieo.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (MILANO)	participant	143˙367.00
10	HUMANITAS UNIVERSITY HUMANITAS UNIVERSITY Organization address address: VIA RITA LEVI MONTALCINI SNC city: PIEVE EMANUELE postcode: 20090 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (PIEVE EMANUELE)	participant	114˙693.00

Map

Project objective

In the European Union, cancer is the leading cause of death and the overall cancer incidence is still increasing. As a result of expanding efforts to improve cancer outcome, a main paradigm change is occurring in cancer therapy towards individualized medicine. Antibody-based therapies form an integral and constantly growing part of this approach. Antibody-based therapies will strongly influence the coming decade of cancer care. The importance of immunotherapy has been highlighted by the prestigious Science journal as “breakthrough of the year 2013”, heralding the rising importance of immunotherapy. Accordingly the need for well-trained and skilled researchers in academia and industry is dramatically increasing in this field. IMMUTRAIN is a training network bringing together experts in the fields of monoclonal antibodies, dendritic cells, T-cells and immunomodulatory nucleic acids with a considerable industrial involvement. The network comprises nine academic research groups and five industrial partners in a total of seven European countries. IMMUTRAIN will actively create synergies between those sectors by forming and promoting young researchers to match the challenges of immunotherapies. Particular focus will be placed on combinatorial therapies and on the new emerging field of bispecific antibodies used to target both the tumor and the patient´s immune system. Fifteen Ph. D. students (early stage researchers, ESR) reinforced by the project leaders will investigate innovative therapeutic strategies and provide the rationale for future clinical trials. Throughout their projects, ESR will learn to integrate academic and industrial aspects and will sharpen their experimental and complementary skills in a well-designed and diversified training program.

Deliverables

List of deliverables.
One manuscript on the combination of antibodies with T cells submitted for publication	Documents, reports	2020-03-06 16:55:36
One manuscript on new formulations of antibodies to activate immune cells submitted for publication	Documents, reports	2020-03-06 16:55:40
One manuscript on the combination of antibodies with dendritic cell therapy submitted for publication	Documents, reports	2020-03-06 16:55:36
One manuscript on the combination of antibodies with therapeutic nucleic acids submitted for publication	Documents, reports	2020-03-06 16:55:42
IMMUTRAIN position paper	Documents, reports	2020-03-06 16:55:34
supervisory board	Other	2020-02-20 17:41:01
Reports on conferences on the homepage	Documents, reports	2020-02-20 17:41:01

Take a look to the deliverables list in detail: detailed list of IMMUTRAIN deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2018	Jayakumar Vadakekolathu, Shaymaa Ismael Kadhim Al-Juboori, Catherine Johnson, Anne Schneider, Magdalena ElÅ¼bieta Buczek, Anna Di Biase, Alan Graham Pockley, Graham Roy Ball, Desmond George Powe, Tarik Regad MTSS1 and SCAMP1 cooperate to prevent invasion in breast cancer published pages: 9(3):344, ISSN: 2041-4889, DOI: 10.1038/s41419-018-0364-9	Cell Death & Disease 9/3	2020-02-20
2019	Luisa Barbato, Marco Bocchetti, Anna Di Biase, Tarik Regad Cancer Stem Cells and Targeting Strategies published pages: 926, ISSN: 2073-4409, DOI: 10.3390/cells8080926	Cells 8/8	2020-02-20
2018	Sebastian Kobold, Stanislav Pantelyushin, Felicitas Rataj, Johannes vom Berg Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy published pages: , ISSN: 2234-943X, DOI: 10.3389/fonc.2018.00285	Frontiers in Oncology 8	2020-02-20
2019	Mohamed-Reda Benmebarek, Clara Karches, Bruno Cadilha, Stefanie Lesch, Stefan Endres, Sebastian Kobold Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells published pages: 1283, ISSN: 1422-0067, DOI: 10.3390/ijms20061283	International Journal of Molecular Sciences 20/6	2020-02-20
2017	David Olmeda, Daniela Cerezo-Wallis, Erica Riveiro-Falkenbach, Paula C. Pennacchi, Marta Contreras-Alcalde, Nuria Ibarz, Metehan Cifdaloz, Xavier Catena, Tonantzin G. Calvo, Estela CaÃ±Ã³n, Direna Alonso-Curbelo, Javier Suarez, Lisa Osterloh, Osvaldo GraÃ±a, Francisca Mulero, Diego MegÃas, Marta CaÃ±amero, Jorge L. MartÃnez-Torrecuadrada, Chandrani Mondal, Julie Di Martino, David Lora, InÃ©s Mar Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine published pages: 676-680, ISSN: 0028-0836, DOI: 10.1038/nature22977	Nature 546/7660	2020-02-20
2019	Michael Ruzicka, Lars M. Koenig, Simone Formisano, Daniel F. R. Boehmer, Binje Vick, Eva-M. Heuer, Hanna Meinl, Lorenz Kocheise, Marcus ZeitlhÃ¶fler, Julia Ahlfeld, Sebastian Kobold, Stefan Endres, Marion Subklewe, Peter Duewell, Max Schnurr, Irmela Jeremias, Felix S. Lichtenegger, Simon Rothenfusser RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade published pages: , ISSN: 0887-6924, DOI: 10.1038/s41375-019-0639-x	Leukemia	2020-02-20
2019	Clara H. Karches, Mohamed-Reda Benmebarek, Moritz L. Schmidbauer, Mathias Kurzay, Richard Klaus, Martina Geiger, Felicitas Rataj, Bruno L. Cadilha, Stefanie Lesch, Constanze Heise, Ramona Murr, Johannes vom Berg, Martin Jastroch, Daniel Lamp, Jian Ding, Peter Duewell, Gerhard Niederfellner, Claudio Sustmann, Stefan Endres, Christian Klein, Sebastian Kobold Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy published pages: 5890-5900, ISSN: 1078-0432, DOI: 10.1158/1078-0432.ccr-18-3927	Clinical Cancer Research 25/19	2020-02-20
2019	Lydia Bellmann, Giuseppe Cappellano, Johanna F. Schachtlâ€Riess, Anastasia Prokopi, Athanasios Seretis, Daniela Ortner, Christoph H. Tripp, Constance E. Brinckerhoff, David W. Mullins, Patrizia Stoitzner A TLR7 agonist strengthens T and NK cell function during BRAFâ€targeted therapy in a preclinical melanoma model published pages: 1409-1420, ISSN: 0020-7136, DOI: 10.1002/ijc.32777	International Journal of Cancer 146/5	2020-02-20
2019	Stefan Stoiber, Bruno L. Cadilha, Mohamed-Reda Benmebarek, Stefanie Lesch, Stefan Endres, Sebastian Kobold Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy published pages: 472, ISSN: 2073-4409, DOI: 10.3390/cells8050472	Cells 8/5	2020-02-20
2017	Cornelia Voigt, Peter May, Adrian Gottschlich, Anamarija Markota, Daniel Wenk, Inga Gerlach, Sebastian Voigt, Georgios T. Stathopoulos, Kristina A. M. Arendt, Constanze Heise, Felicitas Rataj, Klaus-Peter Janssen, Melanie KÃ¶nigshoff, Hauke Winter, Isabelle Himsl, Wolfgang E. Thasler, Max Schnurr, Simon RothenfuÃŸer, Stefan Endres, Sebastian Kobold Cancer cells induce interleukin-22 production from memory CD4 + T cells via interleukin-1 to promote tumor growth published pages: 12994-12999, ISSN: 0027-8424, DOI: 10.1073/pnas.1705165114	Proceedings of the National Academy of Sciences 114/49	2020-02-20
2019	Diana Darowski, Christian Jost, Kay Stubenrauch, Uwe Wessels, JÃ¶rg Benz, Andreas Ehler, Anne Freimoser-Grundschober, Peter BrÃ¼nker, Ekkehard MÃ¶ssner, Pablo UmaÃ±a, Sebastian Kobold, Christian Klein P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation published pages: , ISSN: 1741-0126, DOI: 10.1093/protein/gzz027	Protein Engineering, Design and Selection	2020-02-20
2019	Philipp Metzger, Sabrina V. Kirchleitner, Michael Kluge, Lars M. Koenig, Christine HÃ¶rth, Carlotta A. Rambuscheck, Daniel BÃ¶hmer, Julia Ahlfeld, Sebastian Kobold, Caroline C. Friedel, Stefan Endres, Max Schnurr, Peter Duewell Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer published pages: 7:288, ISSN: 2051-1426, DOI: 10.1186/s40425-019-0778-7	Journal for ImmunoTherapy of Cancer 7/1	2020-02-20
2019	Torben Heise, Johan F. A. Pijnenborg, Christian BÃ¼ll, Niek van Hilten, Esther D. Kers-Rebel, Natasja Balneger, Hidde Elferink, Gosse J. Adema, Thomas J. Boltje Potent Metabolic Sialylation Inhibitors Based on C-5-Modified Fluorinated Sialic Acids published pages: 1014-1021, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.8b01757	Journal of Medicinal Chemistry 62/2	2020-02-20
2019	Xiao Liu, Junjian Li, Bruno Loureiro Cadilha, Anamarija Markota, Cornelia Voigt, Zhe Huang, Peter P. Lin, Daisy D. Wang, Juncheng Dai, Gisela Kranz, Anna Krandick, Darko Libl, Horst Zitzelsberger, Isabella Zagorski, Herbert Braselmann, Min Pan, Sibo Zhu, Yuanchi Huang, Sebastian Niedermeyer, Christoph A. Reichel, Bernd Uhl, Daria Briukhovetska, Javier SuÃ¡rez, Sebastian Kobold, Olivier Gires, Hong Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis published pages: eaav4275, ISSN: 2375-2548, DOI: 10.1126/sciadv.aav4275	Science Advances 5/6	2020-02-20
2018	Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, Connie P. M. Duong, Maryam Tidjani Alou, Romain DaillÃ¨re, AurÃ©lie Fluckiger, Meriem Messaoudene, Conrad Rauber, Maria P. Roberti, Marine Fidelle, Caroline Flament, Vichnou Poirier-Colame, Paule Opolon, Christophe Klein, Kristina Iribarren, Laura MondragÃ³n, Nicolas Jacquelot, Bo Qu, Gladys Ferrere, CÃ©line ClÃ©menson, Laura Mezquita, Jordi Re Gut microbiome influences efficacy of PD-1â€“based immunotherapy against epithelial tumors published pages: 91-97, ISSN: 0036-8075, DOI: 10.1126/science.aan3706	Science 359/6371	2020-02-20
2018	Christian BÃ¼ll, Thomas J Boltje, Natasja Balneger, Sarah M Weischer, Melissa Wassink, Jasper J van Gemst, Victor R.L.J Bloemendal, Louis Boon, Johan van der Vlag, Torben Heise, Martijn H den Brok, Gosse J. Adema Sialic acid blockade suppresses tumor growth by enhancing T cell-mediated tumor immunity published pages: canres.3376.2017, ISSN: 0008-5472, DOI: 10.1158/0008-5472.can-17-3376	Cancer Research	2020-02-20
2019	Marlies J.W. Peeters, Donata Dulkeviciute, Arianna Draghi, Cathrin Ritter, Anne Rahbech, Signe K. Skadborg, Tina Seremet, Ana Micaela Carnaz SimÃµes, Evelina Martinenaite, HÃ³lmfridur R. HalldÃ³rsdÃ³ttir, Mads Hald Andersen, Gitte Holmen Olofsson, Inge Marie Svane, Lene Juel Rasmussen, Ã–zcan Met, JÃ¼rgen C. Becker, Marco Donia, Claus Desler, Per thor Straten MERTK Acts as a Costimulatory Receptor on Human CD8 + T Cells published pages: 1472-1484, ISSN: 2326-6066, DOI: 10.1158/2326-6066.cir-18-0841	Cancer Immunology Research 7/9	2020-02-20
2018	Adrian Gottschlich, Stefan Endres, Sebastian Kobold Can we use interleukin-1Î² blockade for lung cancer treatment? published pages: S160-S164, ISSN: 2218-6751, DOI: 10.21037/tlcr.2018.03.15	Translational Lung Cancer Research 7/S2	2020-02-20

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUTRAIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUTRAIN" are provided by the European Opendata Portal: CORDIS opendata.